Application of the Marin model to the current study group
. | . | Estimated 4-y rate, % . | . | |
---|---|---|---|---|
Study and risk group . | No. (%) . | Progression-free . | Survival . | |
University of Texas M. D. Anderson* | ||||
Good | 132 (60) | 94 | 96 | |
Intermediate | 60 (27) | 72 | 86 | |
Poor | 27 (12) | 30 | 49 | |
Marin38 | ||||
Good | 108 (49) | 93 | 94 | |
Intermediate | 87 (39) | 61 | 75 | |
Poor | 26 (12) | 89 | 100 |
. | . | Estimated 4-y rate, % . | . | |
---|---|---|---|---|
Study and risk group . | No. (%) . | Progression-free . | Survival . | |
University of Texas M. D. Anderson* | ||||
Good | 132 (60) | 94 | 96 | |
Intermediate | 60 (27) | 72 | 86 | |
Poor | 27 (12) | 30 | 49 | |
Marin38 | ||||
Good | 108 (49) | 93 | 94 | |
Intermediate | 87 (39) | 61 | 75 | |
Poor | 26 (12) | 89 | 100 |
Adverse factors: prior hematologic resistance to IFN-α, splenomegaly, and no cytogenetic response to imatinib mesylate (Ph- positive > 90%) after 3 months of imatinib mesylate therapy.
Good indicates no adverse factors; intermediate, 1 adverse factor; poor, 2 or 3 adverse factors.